Physician profile
Pablo Reyes
NPI 1891729786
$3,066.12
in general payments reported to CMS, 2019-2025
32 companies · $1,025 in 2025
The $1,025 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $96.08 · 2021: $189 · 2022: $190 · 2023: $351 · 2024: $832 · 2025: $1,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,194 · Education: $15.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,193.53 |
| Education | $15.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $387.38 | 2024-2025 | |
| Celgene Corporation | $257.10 | 2022-2025 | Reblozyl, Opdualag |
| Avinger INC. | $244.08 | 2019-2021 | |
| Janssen Biotech, INC. | $213.05 | 2019-2025 | Rybrevant, Carvykti |
| Shockwave Medical, INC | $172.84 | 2022 | |
| Boston Scientific Corporation | $168.17 | 2023 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $148.30 | 2019-2025 | Opdivo, Opdualag |
| Abiomed | $145.86 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $133.60 | 2019-2023 | |
| Astellas Pharma US INC | $126.65 | 2020-2025 | Xtandi, Vyloy, Padcev |
| Genzyme Corporation | $118.56 | 2024-2025 | |
| Dendreon Pharmaceuticals LLC | $95.27 | 2024 | Provenge |
| Pfizer INC. | $94.77 | 2023-2025 | |
| Array Biopharma INC | $93.00 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Abbvie INC. | $81.60 | 2024-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $79.25 | 2024-2025 | Enhertu, Vanflyta |
| Beone Medicines USA, INC. | $76.26 | 2025 | Brukinsa |
| Incyte Corporation | $73.39 | 2025 | Jakafi, Zynyz, Monjuvi |
| Eisai INC. | $56.33 | 2025 | |
| Blueprint Medicines Corporation | $33.71 | 2025 | Ayvakit |
| Regeneron Healthcare Solutions, INC. | $33.20 | 2025 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $29.07 | 2024 | Andexxa |
| Taiho Oncology, INC. | $28.87 | 2025 | |
| Glaxosmithkline, LLC. | $28.61 | 2025 | Blenrep, Ojjaara |
| Mirati Therapeutics, INC. | $24.69 | 2024 | Krazati |
| Genentech USA, INC. | $23.00 | 2024 | Polivy |
| Aurobindo Pharma USA, INC. | $20.16 | 2020 | |
| Sanofi-Aventis U.S. LLC | $18.26 | 2019 | |
| Merck Sharp & Dohme LLC | $17.64 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.28 | 2019 | |
| Amgen INC. | $15.25 | 2025 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pablo Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.